1644-

AMENDMENT TRANSMITTAL LETTER (Signal Entity) Applicant(s): Richard Weisbart, et al.					Docket No. 13589	
		ng Date () ber 28, 2001	ng Date (Examiner		Group Art Unit 1644	
Invention: TREATMENT OF IMMUNE-MEDIATED DISEASES BY ORAL ADMINISTRATION OF PLASMA FRACTIONS ENRICHED IN IMMUNOGLOBULIN G						
TO THE COMMISSIONER FOR PATENTS:						
 Transmitted herewith is an amendment in the above-identified application. Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted. □ A verified statement to establish Small Entity status under 37 FR 1.27 is enclosed. The fee has been calculated and is transmitted as shown below. 						
		CLAIMS AS AM	ENDED			
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT		RATE	ADDITIONAL FEE
TOTAL CLAIMS	27 -	27 =		+~-	\$9.00	
INDEP. CLAIMS	6 -	6 =	0	х	\$43.0	
Multiple Depender	nt Claims (check if appl	TOTAL ADDITIONAL F	FFF FOR THIS AM			\$0.00 \$0.00
 No additional fee is required for amendment. □ Please charge Deposit Account No. in the amount of □ A check in the amount of to cover the filing fee is enclosed. ☑ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 19-3886/RCT ☑ Any additional filing fees required under 37 C.F.R. 1.16. ☑ Any patent application processing fees under 37 CFR 1.17. Dated: October 23, 2003						
Peter I. Bernstein Registration No. 4 Scully, Scott, Mur 400 Garden City I Garden City, New (516) 742-4343	43,497 rphy & Presser Plaza		orOct. 23, 200: first class mai Commissione 22313-1450.	ail und er for auture	der 37 C.F. Patents, F	ent and fee is being deposited with the U.S. Postal Service as F.R. 1.8 and is addressed to the P.O. Box 1450, Alexandria, VA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Richard Weisbart, et al. Applicants:

Examiner:

J. Roark

Serial No.:

09/966,119

Art Unit:

1644

Filed:

September 28, 2001

Docket:

13589

For:

TREATMENT OF IMMUNE-MEDIATED

Dated:

October 23, 2003

DISEASES BY ORAL ADMINISTRATION OF

PLASMA FRACTIONS ENRICHED IN

IMMUNOGLOBULIN G

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

RESPONSE PURSUANT TO 37 C.F.R. §§ 1.111 and 1.143

Sir:

In response to the Office Action dated September 26, 2003, setting forth a requirement for restriction and in accordance with the provisions of 37 C.F.R. §§ 1.111 and 1.143, Applicants provisionally elect, with traverse, Group II, Claims 8-9, 17-18 and 26-28, directed to immunoglobulin compositions comprising Cohn Fraction II+III.

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on October 23, 2003.

Dated: October 23, 2003